AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas

AstraZeneca's focus on improving manufacturing efficiencies, on the heels of similar moves by Merck and Pfizer, may signal that manufacturing is the next target for industry cost-cutting initiatives